Compare Micron Technology, Inc. (MU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Organon & Co. Common Stock — how do they compare? Micron Technology, Inc. trades at $881.85 (market cap $1.08T), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Micron Technology, Inc. is far larger — about 298.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 49 Days and Organon & Co. Common Stock for 0 Days on average.
| MU | OGN | |
|---|---|---|
Market Cap | $1.08T | $3.62B |
Volume | 28,906,235 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $1.21K | $13.81 |
52-Week Low | $191.94 | $5.70 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.04T | $11.04B |
Dividend Yield | 0.06% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
